Sana Biotechnology (SANA) Debt Ratio (2021 - 2026)

Sana Biotechnology recorded quarterly Debt Ratio of 0.14 in Q1 2026, up 48.66% quarter-over-quarter from 0.1 in Q4 2025.

Sana Biotechnology's Debt Ratio history runs 5 years deep, the most recent figure standing at 0.14 for Q1 2026.

  • In Q1 2026, Debt Ratio changed N/A year-over-year to 0.14; the TTM figure through Mar 2026 stood at 0.14 (changed N/A YoY), while the FY2025 annual figure was 0.1, changed N/A from the prior year.
  • Debt Ratio came in at 0.14 for Q1 2026 at Sana Biotechnology, up from 0.1 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.14 in Q1 2026 to a low of 0.05 in Q1 2022.
  • A 4-year average of 0.08 and a median of 0.07 in 2023 frame the typical range for Debt Ratio.
  • On a YoY basis, Debt Ratio climbed as much as 87.7% in 2022 and fell as far as 47.87% in 2022.
  • Sana Biotechnology's Debt Ratio stood at 0.07 in 2022, then climbed by 22.8% to 0.08 in 2023, then gained by 16.73% to 0.1 in 2025, then jumped by 48.66% to 0.14 in 2026.
  • According to Business Quant data, Debt Ratio over the past three periods registered 0.14, 0.1, and 0.08 for Q1 2026, Q4 2025, and Q2 2023 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.18
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 1.41
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.05
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Sana Biotechnology 890.09 Mn 890.09 Mn - 0.14

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.14
Dec 31, 2025 0.10
Jun 30, 2023 0.08
Mar 31, 2023 0.08
Dec 31, 2022 0.07
Sep 30, 2022 0.07
Jun 30, 2022 0.05
Mar 31, 2022 0.05
Dec 31, 2021 0.05
Sep 30, 2021 0.04